Dendrimer-Based Platform for Effective Capture of Tumor Cells after TGFβ1-Induced Epithelial-Mesenchymal Transition

Ja Hye Myung, Ashley Cha, Kevin A. Tam, Michael Poellmann, Alain Borgeat, Roohollah Sharifi, Robert E. Molokie, Gina Votta-Velis, Seungpyo Hong

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Detection of circulating tumor cells (CTCs) relying on their expression of epithelial cell markers, such as epithelial cell adhesion molecule (EpCAM), has been commonly used. However, this approach unlikely captures CTCs that have undergone the process of epithelial-mesenchymal transition (EMT). In this study, we have induced EMT of in vitro prostate (PCa) and breast cancer (BCa) cell lines by treatment of transforming growth factor β 1 (TGFβ1), a pleiotropic cytokine with transition-regulating activities. We found that the TGFβ1-treated, post-EMT cells exhibited up to a 45% reduction in binding affinity to antibodies against EpCAM (aEpCAM). To overcome this limitation, we designed our capture platform that integrates a unique combination of biomimetic cell rolling, dendrimer-mediated multivalent binding, and antibody cocktails of aEpCAM/aEGFR/aHER-2. Our capture surfaces resulted in up to 98% capture efficiency of post-EMT cells from mixtures of TGFβ1-treated and untreated cancer cells spiked in culture media and human blood. In a clinical pilot study, our CTC device was also able to capture rare CTCs from PCa patients with significantly enhanced capture sensitivity and purity compared to the control surface with aEpCAM only, demonstrating its potential to provide a reliable detection solution for CTCs regardless of their EMT status.

Original languageEnglish
Pages (from-to)8374-8382
Number of pages9
JournalAnalytical Chemistry
Volume91
Issue number13
DOIs
Publication statusPublished - 2019 Jul 2

Fingerprint

Dendrimers
Transforming Growth Factors
Tumors
Cells
Cell Adhesion Molecules
Antibodies
Control surfaces
Biomimetics
Culture Media
Blood
Cytokines
Epithelial Cells

All Science Journal Classification (ASJC) codes

  • Analytical Chemistry

Cite this

Myung, Ja Hye ; Cha, Ashley ; Tam, Kevin A. ; Poellmann, Michael ; Borgeat, Alain ; Sharifi, Roohollah ; Molokie, Robert E. ; Votta-Velis, Gina ; Hong, Seungpyo. / Dendrimer-Based Platform for Effective Capture of Tumor Cells after TGFβ1-Induced Epithelial-Mesenchymal Transition. In: Analytical Chemistry. 2019 ; Vol. 91, No. 13. pp. 8374-8382.
@article{360e271d31ca467eb1b3162fbf4a240d,
title = "Dendrimer-Based Platform for Effective Capture of Tumor Cells after TGFβ1-Induced Epithelial-Mesenchymal Transition",
abstract = "Detection of circulating tumor cells (CTCs) relying on their expression of epithelial cell markers, such as epithelial cell adhesion molecule (EpCAM), has been commonly used. However, this approach unlikely captures CTCs that have undergone the process of epithelial-mesenchymal transition (EMT). In this study, we have induced EMT of in vitro prostate (PCa) and breast cancer (BCa) cell lines by treatment of transforming growth factor β 1 (TGFβ1), a pleiotropic cytokine with transition-regulating activities. We found that the TGFβ1-treated, post-EMT cells exhibited up to a 45{\%} reduction in binding affinity to antibodies against EpCAM (aEpCAM). To overcome this limitation, we designed our capture platform that integrates a unique combination of biomimetic cell rolling, dendrimer-mediated multivalent binding, and antibody cocktails of aEpCAM/aEGFR/aHER-2. Our capture surfaces resulted in up to 98{\%} capture efficiency of post-EMT cells from mixtures of TGFβ1-treated and untreated cancer cells spiked in culture media and human blood. In a clinical pilot study, our CTC device was also able to capture rare CTCs from PCa patients with significantly enhanced capture sensitivity and purity compared to the control surface with aEpCAM only, demonstrating its potential to provide a reliable detection solution for CTCs regardless of their EMT status.",
author = "Myung, {Ja Hye} and Ashley Cha and Tam, {Kevin A.} and Michael Poellmann and Alain Borgeat and Roohollah Sharifi and Molokie, {Robert E.} and Gina Votta-Velis and Seungpyo Hong",
year = "2019",
month = "7",
day = "2",
doi = "10.1021/acs.analchem.9b01181",
language = "English",
volume = "91",
pages = "8374--8382",
journal = "Analytical Chemistry",
issn = "0003-2700",
publisher = "American Chemical Society",
number = "13",

}

Myung, JH, Cha, A, Tam, KA, Poellmann, M, Borgeat, A, Sharifi, R, Molokie, RE, Votta-Velis, G & Hong, S 2019, 'Dendrimer-Based Platform for Effective Capture of Tumor Cells after TGFβ1-Induced Epithelial-Mesenchymal Transition', Analytical Chemistry, vol. 91, no. 13, pp. 8374-8382. https://doi.org/10.1021/acs.analchem.9b01181

Dendrimer-Based Platform for Effective Capture of Tumor Cells after TGFβ1-Induced Epithelial-Mesenchymal Transition. / Myung, Ja Hye; Cha, Ashley; Tam, Kevin A.; Poellmann, Michael; Borgeat, Alain; Sharifi, Roohollah; Molokie, Robert E.; Votta-Velis, Gina; Hong, Seungpyo.

In: Analytical Chemistry, Vol. 91, No. 13, 02.07.2019, p. 8374-8382.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Dendrimer-Based Platform for Effective Capture of Tumor Cells after TGFβ1-Induced Epithelial-Mesenchymal Transition

AU - Myung, Ja Hye

AU - Cha, Ashley

AU - Tam, Kevin A.

AU - Poellmann, Michael

AU - Borgeat, Alain

AU - Sharifi, Roohollah

AU - Molokie, Robert E.

AU - Votta-Velis, Gina

AU - Hong, Seungpyo

PY - 2019/7/2

Y1 - 2019/7/2

N2 - Detection of circulating tumor cells (CTCs) relying on their expression of epithelial cell markers, such as epithelial cell adhesion molecule (EpCAM), has been commonly used. However, this approach unlikely captures CTCs that have undergone the process of epithelial-mesenchymal transition (EMT). In this study, we have induced EMT of in vitro prostate (PCa) and breast cancer (BCa) cell lines by treatment of transforming growth factor β 1 (TGFβ1), a pleiotropic cytokine with transition-regulating activities. We found that the TGFβ1-treated, post-EMT cells exhibited up to a 45% reduction in binding affinity to antibodies against EpCAM (aEpCAM). To overcome this limitation, we designed our capture platform that integrates a unique combination of biomimetic cell rolling, dendrimer-mediated multivalent binding, and antibody cocktails of aEpCAM/aEGFR/aHER-2. Our capture surfaces resulted in up to 98% capture efficiency of post-EMT cells from mixtures of TGFβ1-treated and untreated cancer cells spiked in culture media and human blood. In a clinical pilot study, our CTC device was also able to capture rare CTCs from PCa patients with significantly enhanced capture sensitivity and purity compared to the control surface with aEpCAM only, demonstrating its potential to provide a reliable detection solution for CTCs regardless of their EMT status.

AB - Detection of circulating tumor cells (CTCs) relying on their expression of epithelial cell markers, such as epithelial cell adhesion molecule (EpCAM), has been commonly used. However, this approach unlikely captures CTCs that have undergone the process of epithelial-mesenchymal transition (EMT). In this study, we have induced EMT of in vitro prostate (PCa) and breast cancer (BCa) cell lines by treatment of transforming growth factor β 1 (TGFβ1), a pleiotropic cytokine with transition-regulating activities. We found that the TGFβ1-treated, post-EMT cells exhibited up to a 45% reduction in binding affinity to antibodies against EpCAM (aEpCAM). To overcome this limitation, we designed our capture platform that integrates a unique combination of biomimetic cell rolling, dendrimer-mediated multivalent binding, and antibody cocktails of aEpCAM/aEGFR/aHER-2. Our capture surfaces resulted in up to 98% capture efficiency of post-EMT cells from mixtures of TGFβ1-treated and untreated cancer cells spiked in culture media and human blood. In a clinical pilot study, our CTC device was also able to capture rare CTCs from PCa patients with significantly enhanced capture sensitivity and purity compared to the control surface with aEpCAM only, demonstrating its potential to provide a reliable detection solution for CTCs regardless of their EMT status.

UR - http://www.scopus.com/inward/record.url?scp=85068110563&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068110563&partnerID=8YFLogxK

U2 - 10.1021/acs.analchem.9b01181

DO - 10.1021/acs.analchem.9b01181

M3 - Article

C2 - 31247718

AN - SCOPUS:85068110563

VL - 91

SP - 8374

EP - 8382

JO - Analytical Chemistry

JF - Analytical Chemistry

SN - 0003-2700

IS - 13

ER -